Immunic eyes key data readout from multiple sclerosis trial in 2025
Portfolio Pulse from
Immunic Inc (NASDAQ:IMUX) has made significant progress in 2024, advancing its therapy vidofludimus calcium and securing funding. The company anticipates key data from its Phase 2 CALLIPER trial in progressive multiple sclerosis by April 2025.
January 07, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunic Inc has advanced its therapy vidofludimus calcium and secured funding, with key data from the Phase 2 CALLIPER trial expected in April 2025.
The announcement of key data readouts in 2025 and the securing of significant funding are positive developments for Immunic Inc. These milestones suggest potential future success in their clinical programs, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100